Compare WPRT & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | PRPO |
|---|---|---|
| Founded | 1995 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6M | 42.0M |
| IPO Year | 2006 | 2000 |
| Metric | WPRT | PRPO |
|---|---|---|
| Price | $1.93 | $23.30 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.66 | N/A |
| AVG Volume (30 Days) | 53.3K | ★ 120.8K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | $9.35 | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $1.54 | $16.40 |
| 52 Week High | $2.55 | $33.63 |
| Indicator | WPRT | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | N/A |
| Support Level | $1.74 | N/A |
| Resistance Level | $2.12 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 55.56 | 0.00 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.